IRVINE, Calif.----Allergan, Inc. today announced the United States Food and Drug Administration has approved LUMIGAN® 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.